1 / 13

The second half What happens after research is complete?

The second half What happens after research is complete?. HCMDSS Workshop June 3, 2005 Sherman Eagles – Medtronic, Inc. Barriers. Medical device manufacturers resist new techniques and methods No incentives to cooperate Legal and regulatory obstacles to collaboration.

marva
Download Presentation

The second half What happens after research is complete?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The second halfWhat happens after research is complete? HCMDSS Workshop June 3, 2005 Sherman Eagles – Medtronic, Inc.

  2. Barriers • Medical device manufacturers resist new techniques and methods • No incentives to cooperate • Legal and regulatory obstacles to collaboration

  3. Factors making MD manufacturers resistant to technology transfer • Lack of awareness • Conservative nature • Short development cycle

  4. Lack of awareness • Software is not a problem • Far more deaths due to poorly designed human systems (not much change 5 years after IOM report) • Most regulatory actions are due to manufacturing • Most common software error is mis-identification • No data that shows software is a problem • Software is not a critical technology • Customers don’t buy software, they buy devices • Software is easy

  5. Conservative nature • Regulatory premarket approval • Don’t change what works • Lack of predictability costs lots of money • Liability issues • Will always be sued • Legacy application • New products are built from previous product

  6. Short development cycle • Competition • New features sell products • Health care cost containment • New products are needed to maintain higher average selling prices

  7. Lack of incentive • IP is a key asset – not much value in working with researchers if they keep the IP • ROI must be greater than alternative ways to spend the money • ROI must be relatively short term

  8. Legal and regulatory barriers • Liability • Responsibility and ownership not clear • Anti-trust • No good mechanisms for working with competitors • Regulation focused on individual devices, not systems

  9. What can we do? • Recognize and address the “product” system • Researchers, manufacturers, regulators, legal system, customers and end users • Remove or reduce barriers • NGOs or consortium to hold IP and allow competitors to work together • New regulatory models that allow flexibility • Gather data on software problems

  10. Develop standards • Manufacturers pay attention to guidance from FDA and EU notified bodies. • FDA and EU rely on standards developing organizations for experience and expertise • FDA and EU participate on SDOs • Support participation by users and academia

  11. Provide incentives for manufacturers to adopt research results • Use purchasing power • VA network security requirements • Streamline regulatory approvals

  12. In Summary • Research only gets us half way there • We also need to recognize and address the system that creates products and delivers the new research to the marketplace

  13. Contact Information Sherman Eagles Technical Fellow Medtronic, Inc 7000 NE Central Ave Minneapolis, MN 55432 763-514-4250 763-514-6197 (fax) sherman.eagles@medtronic.com

More Related